Herbert Hurwitz
Adjunct Professor in the Department of Medicine · Duke University Hospital
Credentials: · ·
History
Research
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
New England Journal of Medicine · 2004 · First of 15 authors · Corresponding · 8,376 citations
Journal of Clinical Oncology · 2003 · 1,359 citations
Review · Cancer Treatment Reviews · 2020 · 941 citations
43 papers
- JB
31 papers · 6 as a fellow
- FK
23 papers
22 papers
21 papers
17 papers
16 papers
- LS
16 papers
Grants
- 2014–2019
National Cancer Institute · UM1
Contact PI · $707.3K · Duke University
- 2006–2012
Anti-VEGF in Tumors & Wounds: Efficacy vs Toxicity
National Cancer Institute · R01
Contact PI · $2.1M · Duke University
- 2006–2011
Wound Angiogenesis as a Biomarker for Tumor Angiogenesis
National Cancer Institute · K24
Contact PI · $613.3K · Duke University
- 2003–2006
Does NO Mediate Clinical Anti-VEGF Vascular Effects
National Cancer Institute · R21
Contact PI · $542.2K · Duke University
Clinical trials
- 2014–2016
Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer
Principal investigator · Completed · Phase 1
Duke University
- 2011–2014
Dose Escalation Study of Pazopanib Plus TH-302
Principal investigator · Completed · Phase 1
Herbert Hurwitz, MD
- 2010–2012
Treatment of Palmar Plantar Erythrodysesthesia (PPE) With Topical Sildenafil
Principal investigator · Completed · Phase 1
Duke University
- 2010–2018
Principal investigator · Completed · Phase 1
Jeffrey Clarke